疾病机制：血管生成与乳腺癌的治疗

Mechanisms of disease: angiogenesis and the management of breast cancer.

作者信息

Banerjee Susana, Dowsett Mitch, Ashworth Alan, Martin Lesley-Ann

机构信息

Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, UK.

出版信息

Nat Clin Pract Oncol. 2007 Sep;4(9):536-50. doi: 10.1038/ncponc0905.

DOI:10.1038/ncponc0905

PMID:17728712

Abstract

Demonstration of the clinically significant activity of bevacizumab in breast cancer has attracted a great deal of interest. Numerous other antiangiogenic treatments are in clinical development and some established therapies including tamoxifen and trastuzumab might function, in part, by suppressing angiogenesis. In this Review, we discuss the potential of various components of the angiogenic pathway as prognostic and predictive factors in breast cancer. In addition, we describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimum use of these agents for the treatment of breast cancer.

摘要

贝伐单抗在乳腺癌中具有临床显著活性的证明引起了广泛关注。许多其他抗血管生成治疗正在临床开发中，一些已确立的疗法，包括他莫昔芬和曲妥珠单抗，可能部分通过抑制血管生成发挥作用。在本综述中，我们讨论血管生成途径的各种成分作为乳腺癌预后和预测因素的潜力。此外，我们描述了抗血管生成药物的现有临床试验以及这些药物在乳腺癌治疗的临床开发和最佳使用中面临的挑战。